[go: up one dir, main page]

PE20030305A1 - Inhibidores de polimerasas viricas - Google Patents

Inhibidores de polimerasas viricas

Info

Publication number
PE20030305A1
PE20030305A1 PE2002000663A PE2002000663A PE20030305A1 PE 20030305 A1 PE20030305 A1 PE 20030305A1 PE 2002000663 A PE2002000663 A PE 2002000663A PE 2002000663 A PE2002000663 A PE 2002000663A PE 20030305 A1 PE20030305 A1 PE 20030305A1
Authority
PE
Peru
Prior art keywords
alkyl
cycloalkyl
compounds
cyclohexil
indol
Prior art date
Application number
PE2002000663A
Other languages
English (en)
Inventor
Pierre Louis Beaulieu
Youla S Tsantrizos
Martin Poirier
George Kukolj
Gulrez Fazal
Sylvie Goulet
Marc-Andre Poupart
Jean Rancourt
Eric Jolicoeur
James Gillard
Original Assignee
Boehringer Ingelheim Ca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26975871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20030305(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Ca Ltd filed Critical Boehringer Ingelheim Ca Ltd
Publication of PE20030305A1 publication Critical patent/PE20030305A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS BENZOCONDENSADOS DE FORMULA I DONDE A ES O, S, NR1, CR1; R1 ES H, ALQUILO C1-C6; B ES NR3, Cr3, UNO DE A O B ES CR1 O CR3; R3 ES ALQUILO C1-C6, HALOALQUILO, CICLOALQUILO C3-C7, BICICLOALQUILO C6-C10, ARILO DE 6-10 MIEMBROS, HET, ALQUIL C1-C6-ARILO, ALQUIL C1-C6-HET; R2 ES H, HALOGENO, R21, OR21, SR21, COOR21, SO2N(R22)2, ENTRE OTROS; K ES N, CR4; R4, R5 Y R7 SON H, HALOGENO, ALQUILO C1-C6, HALOALQUILO, CICLOALQUILO C3-C7, ALQUIL C1-C6-CICLOALQUILO C3-C7; R4 ES OR41, SR41, COR41, ENTRE OTROS; L ES N, CR5; M ES N, CR7; Y1 ES O, S; Z ES N(R6a)R6, OR6; R6a ES H, ALQUILO C1-C6, NR61R62; R61 Y R62 SON H, ALQUILO C1-C6, CICLOALQUILO C3-C7, ALQUIL C1-C6-CICLOALQUILO C3-C7, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION; COMPUESTOS INTERMEDIARIOS; UNA COMPOSICION QUE COMPRENDE ADEMAS UN AGENTE INHIBIDOR DE HELICASA DE HCV, POLIMERASA, METALOPROTEASA, IRES, UN AGENTE INMUNOMODULADOR HEREDITARIO (INTERFERONES), RIBAVIRINA, AMANTADINA, UN AGENTE INHIBIDOR DE PROTEASA DE HCV. SON COMPUESTOS PREFERIDOS ESTER METILICO DE ACIDO 3-CICLOHEXIL-2-FURAN-3-IL-1H-INDOL-6-CARBOXILICO; ESTER METILICO DE ACIDO 3-CICLOHEXIL-1-METIL-2-PIRIDIN-2-IL-1H-INDOL-6-CARBOXILICO, ENTRE OTROS. LOS COMPUESTOS SON INHIBIDORES DE POLIMERASAS DE ARN DEPENDIENTE DE ARN DE ENZIMA NS5B
PE2002000663A 2001-07-25 2002-07-25 Inhibidores de polimerasas viricas PE20030305A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30767401P 2001-07-25 2001-07-25
US33806101P 2001-12-07 2001-12-07

Publications (1)

Publication Number Publication Date
PE20030305A1 true PE20030305A1 (es) 2003-04-22

Family

ID=26975871

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000663A PE20030305A1 (es) 2001-07-25 2002-07-25 Inhibidores de polimerasas viricas

Country Status (33)

Country Link
US (5) US7157486B2 (es)
EP (5) EP2335700A1 (es)
JP (4) JP4398725B2 (es)
KR (3) KR100950868B1 (es)
CN (3) CN102424680A (es)
AR (2) AR037495A1 (es)
AT (2) ATE382348T1 (es)
AU (2) AU2002355150B2 (es)
BR (2) BR0211477A (es)
CA (2) CA2450033C (es)
CO (2) CO5650161A2 (es)
CY (2) CY1107354T1 (es)
DE (2) DE60224401T2 (es)
DK (2) DK1414797T3 (es)
EA (2) EA007715B1 (es)
ES (2) ES2299591T3 (es)
HR (3) HRP20090668A2 (es)
HU (2) HUP0401784A3 (es)
IL (4) IL159545A0 (es)
ME (2) MEP59608A (es)
MX (2) MXPA04000731A (es)
MY (1) MY151080A (es)
NO (2) NO327055B1 (es)
NZ (2) NZ531229A (es)
PE (1) PE20030305A1 (es)
PL (2) PL368357A1 (es)
PT (2) PT1414441E (es)
RS (3) RS20090517A (es)
SG (1) SG176999A1 (es)
SI (2) SI1414441T1 (es)
UA (1) UA84256C2 (es)
UY (1) UY27397A1 (es)
WO (2) WO2003010141A2 (es)

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2450628A1 (en) * 2001-06-13 2002-12-19 Genesoft Pharmaceuticals, Inc. Benzothiophene compounds having antiinfective activity
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US7294457B2 (en) * 2001-08-07 2007-11-13 Boehringer Ingelheim (Canada) Ltd. Direct binding assay for identifying inhibitors of HCV polymerase
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7223785B2 (en) * 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) * 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
GB0307891D0 (en) * 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
JP4733023B2 (ja) 2003-04-16 2011-07-27 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルスの大環状イソキノリンペプチド阻害剤
EP1620094A4 (en) * 2003-05-06 2010-04-28 Glaxosmithkline Llc NEW CHEMICAL COMPOUNDS
JP2007501189A (ja) 2003-08-01 2007-01-25 ジェネラブス テクノロジーズ，インコーポレイテッド フラビウイルス科に対する二環式イミダゾール誘導体
WO2005014543A1 (ja) * 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
GB0321003D0 (en) * 2003-09-09 2003-10-08 Angeletti P Ist Richerche Bio Compounds, compositions and uses
US7112601B2 (en) 2003-09-11 2006-09-26 Bristol-Myers Squibb Company Cycloalkyl heterocycles for treating hepatitis C virus
CN1856502A (zh) 2003-09-22 2006-11-01 贝林格尔.英格海姆国际有限公司 抗c型肝炎病毒活性的巨环肽
JP5054382B2 (ja) 2003-10-07 2012-10-24 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン インドール抗ウイルス組成物および方法
GB0323845D0 (en) * 2003-10-10 2003-11-12 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
US20050119318A1 (en) * 2003-10-31 2005-06-02 Hudyma Thomas W. Inhibitors of HCV replication
DK1706403T3 (da) 2003-12-22 2012-04-23 Leuven K U Res & Dev Imidazo[4,5-c]pyridinforbindelser og fremgangsmåder til antiviral behandling
JP4682155B2 (ja) 2004-01-21 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスに対して活性な大環状ペプチド
CN102911161A (zh) * 2004-02-20 2013-02-06 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
PT1719773E (pt) 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
CN1930124A (zh) * 2004-03-08 2007-03-14 贝林格尔·英格海姆药物公司 制备交叉偶联吲哚的方法
CA2558051C (en) * 2004-03-16 2013-03-12 Boehringer Ingelheim International Gmbh Palladium catalyzed indolization of 2-bromo or chloroanilines
GB0413087D0 (en) 2004-06-11 2004-07-14 Angeletti P Ist Richerche Bio Therapeutic compounds
US7781478B2 (en) * 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CA2573185A1 (en) * 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
WO2007084413A2 (en) * 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
PE20060569A1 (es) * 2004-07-16 2006-06-22 Boehringer Ingelheim Int Compuestos de indol carbonilamino como inhibidores de la polimerasa ne5b del vhc
MX2007000762A (es) * 2004-07-22 2007-04-02 Ptc Therapeutics Inc Tienopiridinas para tratamientode hepatitis c.
MX2007001054A (es) 2004-07-27 2007-07-25 Gilead Sciences Inc Imidazo[4,5-d]pirimidinas, sus usos y metodos de preparacion.
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
RU2387655C2 (ru) * 2004-08-09 2010-04-27 Бристол-Маерс Сквибб Компани Ингибиторы репликации вируса гепатита с
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
RU2007130896A (ru) * 2005-01-14 2009-02-20 Дженелэбс Текнолоджиз, Инк. (Us) Индольные производные для лечения вирусных инфекций
EP1853589A1 (en) * 2005-02-11 2007-11-14 Boehringer Ingelheim International Gmbh Process for preparing 2,3-disubstituted indoles
ATE513833T1 (de) 2005-03-02 2011-07-15 Fibrogen Inc Thienopyridinverbindungen und verfahren zu ihrer verwendung
CA2607089A1 (en) 2005-05-04 2006-11-09 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
CN102718744A (zh) 2005-05-13 2012-10-10 Viro化学制药公司 治疗或预防黄病毒感染的组合物和方法
EP1910337A2 (en) * 2005-06-24 2008-04-16 Genelabs Technologies, Inc. Heteroaryl derivatives for treating viruses
EP1915378A4 (en) * 2005-08-12 2009-07-22 Boehringer Ingelheim Int VIRUS POLYMERASE INHIBITORS
US7807838B2 (en) * 2005-08-24 2010-10-05 Pfizer Inc. Methods for the preparation of HCV polymerase inhibitors
WO2007084435A2 (en) * 2006-01-13 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
KR20140089446A (ko) 2006-01-27 2014-07-14 피브로겐, 인크. 저산소증 유발가능 인자(ｈｉｆ)를 안정시키는 시아노이소퀴놀린 화합물
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
JP2009526070A (ja) * 2006-02-09 2009-07-16 シェーリング コーポレイション Ｈｃｖプロテアーゼ阻害薬とｈｃｖポリメラーゼ阻害薬との組み合わせ、ならびにそれらに関連する処置の方法
CA2644389A1 (en) * 2006-03-03 2007-09-20 Schering Corporation Pharmaceutical combinations of hcv-protease and -ires inhibitors
RU2461557C2 (ru) 2006-04-04 2012-09-20 Файброджен, Инк. Соединения пирроло- и тиазолопиридина (варианты) и фармацевтическая композиция на их основе
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
CN101506167A (zh) 2006-08-17 2009-08-12 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
CA2663502A1 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives and methods of use thereof
JP2010505902A (ja) 2006-10-10 2010-02-25 メディヴィル・アクチエボラーグ Ｈｃｖヌクレオシド阻害剤
US20090325145A1 (en) 2006-10-20 2009-12-31 Erwin Sablon Methodology for analysis of sequence variations within the hcv ns5b genomic region
EP2559691A1 (en) 2006-11-15 2013-02-20 Virochem Pharma Inc. Thiophene analogues for the treatment or prevention of Flavivirus infections
KR20090106539A (ko) 2006-12-22 2009-10-09 쉐링 코포레이션 Ｈｃｖ 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체
MX2009006877A (es) 2006-12-22 2009-09-28 Schering Corp Derivados indolicos con anillo unido en las posiciones 5,6 y metodos de uso de los mismos.
KR20090094154A (ko) 2006-12-22 2009-09-03 쉐링 코포레이션 Ｈｃｖ 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체
AU2008216382A1 (en) * 2007-02-12 2008-08-21 Array Biopharma, Inc. Novel inhibitors hepatitis C virus replication
US7998951B2 (en) * 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
CN101679437B (zh) 2007-03-13 2013-04-17 百时美施贵宝公司 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CN101815533A (zh) 2007-05-04 2010-08-25 弗特克斯药品有限公司 用于治疗hcv感染的组合治疗
WO2009018657A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
JP2010535155A (ja) * 2007-08-03 2010-11-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤
CA2697454C (en) 2007-08-29 2015-11-03 Schering Corporation 2-carboxy substituted indole derivatives and methods of use thereof
AU2008295485B2 (en) 2007-08-29 2013-09-05 Merck Sharp & Dohme Corp. 2,3-substituted azaindole derivatives for treating viral infections
CA2697375A1 (en) 2007-08-29 2009-03-12 Schering Corporation 2, 3-substituted indole derivatives for treating viral infections
EP2220095B1 (en) * 2007-11-15 2013-01-02 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
JP5269087B2 (ja) * 2007-11-16 2013-08-21 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルス複製のインヒビター
EP2222660B1 (en) 2007-11-16 2014-03-26 Merck Sharp & Dohme Corp. 3-heterocyclic substituted indole derivatives and methods of use thereof
JP5416708B2 (ja) 2007-11-16 2014-02-12 メルク・シャープ・アンド・ドーム・コーポレーション ３−アミノスルホニル置換インドール誘導体およびそれらの使用方法
CA2708150A1 (en) 2007-12-05 2009-06-18 Enanta Pharmaceuticals, Inc. Fluorinated tripeptide hcv serine protease inhibitors
KR20100098534A (ko) 2007-12-19 2010-09-07 베링거 인겔하임 인터내셔날 게엠베하 바이러스 폴리머라제 억제제
BRPI0821836A2 (pt) 2007-12-24 2015-06-16 Tibotec Pharm Ltd Indóis macrocíclicos como inibidores do vírus da hepatite c
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
MX2010013630A (es) 2008-06-13 2010-12-21 Schering Corp Derivados triciclicos de indol y metodos de uso de los mismos.
BRPI0916216A2 (pt) 2008-07-15 2018-03-13 Novartis Ag composto orgânicos
DK2331554T3 (da) 2008-08-14 2013-05-27 Janssen R & D Ireland Makrocykliske indolderivater, der er anvendelige som hepatitis c-virusinhibitorer
BRPI0918653A2 (pt) * 2008-09-17 2015-12-01 Boehringer Ingelheim Int combinação de inibidor de ns3 protese de hcv com interferon e ribavirina.
JP5649584B2 (ja) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
PE20120207A1 (es) 2008-12-03 2012-03-31 Presidio Pharmaceuticals Inc Derivados de naftaleno, como inhibidores de hcv ns5a
EP2682393A1 (en) 2008-12-03 2014-01-08 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A comprising a bicyclic core.
ES2623016T3 (es) 2008-12-23 2017-07-10 Gilead Pharmasset Llc Fosforamidatos de nucleósido de 2-amino purina 6-O-sustituida
JP6104504B2 (ja) 2008-12-23 2017-03-29 ギリアド ファーマセット エルエルシー ヌクレオシド類似体
MX2011006333A (es) * 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
CN102325783A (zh) * 2008-12-23 2012-01-18 法莫赛特股份有限公司 嘌呤核苷的合成
CN102271699A (zh) 2009-01-07 2011-12-07 西尼克斯公司 用于治疗hcv和hiv感染的环孢菌素衍生物
KR20110120886A (ko) 2009-01-09 2011-11-04 유니버시티 칼리지 오브 카디프 컨설턴트 리미티드 바이러스 감염 치료용 구아노신 뉴클레오사이드 화합물의 포스포라미데이트 유도체
US8314135B2 (en) * 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
WO2010091413A1 (en) * 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8188132B2 (en) * 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8242156B2 (en) * 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8101643B2 (en) * 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
WO2010111483A1 (en) * 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus replication
US20190127365A1 (en) 2017-11-01 2019-05-02 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus replication
US9150554B2 (en) 2009-03-27 2015-10-06 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis C
WO2010114896A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted indolo-pyridinone compounds
EP2417133A1 (en) * 2009-04-06 2012-02-15 PTC Therapeutics, Inc. Compounds and methods for antiviral treatment
EP2419404B1 (en) * 2009-04-15 2015-11-04 AbbVie Inc. Anti-viral compounds
MX2011012155A (es) 2009-05-13 2012-02-28 Enanta Pharm Inc Compuestos macrociclicos como inhibidores del virus de hepatitis c.
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
EP2337781B1 (en) * 2009-06-11 2014-07-23 AbbVie Bahamas Ltd. Anti-viral compounds to treat hcv infection
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8927709B2 (en) * 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) * 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) * 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) * 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US9156818B2 (en) * 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
JP2013508425A (ja) 2009-10-30 2013-03-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｉ２０１３３５、インターフェロンアルファおよびリバビリンを含むｈｃｖの併用療法のための投薬処置計画
BR112012011221A2 (pt) 2009-11-14 2016-04-05 Hoffmann La Roche biomarcadores para prever resposta rápida ao tratamento de hcv
WO2011068715A1 (en) 2009-11-25 2011-06-09 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
EP2507636A1 (en) 2009-12-02 2012-10-10 F. Hoffmann-La Roche AG Biomarkers for predicting sustained response to hcv treatment
EP2512480A4 (en) * 2009-12-14 2013-05-15 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US20130072523A1 (en) 2009-12-24 2013-03-21 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
BR112012018529A2 (pt) 2010-01-25 2016-08-09 Enanta Pharm Inc inibidores do vírus de hepatite c, sua composição farmacêutica e seu uso, e método para inibição da replicação de um vírus contendo rna
CN101775003B (zh) * 2010-02-04 2013-12-04 银杏树药业(苏州)有限公司 苯并噻吩类衍生物及其制备方法和应用
US8623814B2 (en) * 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
US8178531B2 (en) * 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
KR20120124495A (ko) * 2010-03-04 2012-11-13 이난타 파마슈티칼스, 인코포레이티드 Ｈｃｖ 복제의 억제제로서의 조합 제약 작용제
EP2550262A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
CA2794145A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
EP2550268A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
MX2012010919A (es) 2010-03-24 2013-02-01 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones por flavivirus.
PL2609923T4 (pl) 2010-03-31 2017-11-30 Gilead Pharmasset Llc Proces krystalizacji 2-(((s)-(perfluorofenoksy) (fenoksy)fosforylo)amino)propanianu (s)-izopropylu
MX350725B (es) 2010-03-31 2017-09-14 Gilead Pharmasset Llc Fosforamidatos de nucleosido.
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
WO2011127350A1 (en) 2010-04-09 2011-10-13 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
AR082453A1 (es) 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
WO2011149856A1 (en) 2010-05-24 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
EP2575819A4 (en) 2010-06-04 2013-11-27 Enanta Pharm Inc INHIBITORS OF HEPATITIS C VIRUS
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
WO2011159826A2 (en) 2010-06-15 2011-12-22 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
EP2585448A1 (en) 2010-06-28 2013-05-01 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
AR081691A1 (es) 2010-06-28 2012-10-10 Vertex Pharma Derivados de tiofeno, metodos para su preparacion y su uso en el tratamiento o la prevencion de infecciones por flavivirus
EP2603080A4 (en) 2010-08-12 2014-01-22 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
AR082619A1 (es) 2010-08-13 2012-12-19 Hoffmann La Roche Inhibidores del virus de la hepatitis c
MX2013001869A (es) 2010-08-17 2013-06-28 Vertex Pharma Compuestos y metodos para el tratamiento o prevencion de infecciones virales por flaviviridae.
GB201015411D0 (en) 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
EP2618831B1 (en) 2010-09-21 2016-01-06 Enanta Pharmaceuticals, Inc. Macrocyclic proline derived hcv serine protease inhibitors
AU2011305655B2 (en) 2010-09-22 2015-11-05 Alios Biopharma, Inc. Substituted nucleotide analogs
KR20130116245A (ko) * 2010-09-30 2013-10-23 베링거 인겔하임 인터내셔날 게엠베하 Ｈｃｖ 감염 치료용 병용 요법
SG188376A1 (en) 2010-09-30 2013-04-30 Boehringer Ingelheim Int Solid state forms of a potent hcv inhibitor
EA025151B1 (ru) 2010-10-26 2016-11-30 Пресидио Фармасьютикалс, Инк. Ингибиторы вируса гепатита с
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
EP2658857B1 (en) 2010-12-29 2016-11-02 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EP2709455A4 (en) 2011-05-18 2014-11-05 Enanta Pharm Inc PROCESSES FOR THE PREPARATION OF 5-AZASPIRO [2.4] HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES
WO2012175581A1 (en) 2011-06-24 2012-12-27 F. Hoffmann-La Roche Ag Antiviral compounds
WO2013016492A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Thiophene compounds
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
NZ623396A (en) 2011-09-16 2016-07-29 Gilead Pharmasset Llc Methods for treating hcv
EP2766365A1 (en) 2011-10-10 2014-08-20 F.Hoffmann-La Roche Ag Antiviral compounds
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
BR112014013649A2 (pt) 2011-12-06 2020-10-27 The Board Of Trustees Of The Leland Stanford Junior University métodos e agentes para o tratamento de doenças virais e usos dos referidos agentes
WO2013087743A1 (en) 2011-12-16 2013-06-20 F. Hoffmann-La Roche Ag Inhibitors of hcv ns5a
WO2013092481A1 (en) 2011-12-20 2013-06-27 F. Hoffmann-La Roche Ag 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
CN104011060A (zh) 2011-12-20 2014-08-27 弗·哈夫曼-拉罗切有限公司 作为hcv rna复制抑制剂的4‘-叠氮基,3’-氟取代的核苷衍生物
WO2013096680A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
JP6092261B2 (ja) 2012-02-24 2017-03-08 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ウイルス化合物
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
WO2013147749A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient subgenotype populations
WO2013147750A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
US20130261134A1 (en) * 2012-03-30 2013-10-03 Boehringer Ingelheim International Gmbh Mesylate salt forms of a potent hcv inhibitor
US9064551B2 (en) 2012-05-15 2015-06-23 Micron Technology, Inc. Apparatuses and methods for coupling load current to a common source
US8976594B2 (en) 2012-05-15 2015-03-10 Micron Technology, Inc. Memory read apparatus and methods
US20140010783A1 (en) 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
US9064577B2 (en) 2012-12-06 2015-06-23 Micron Technology, Inc. Apparatuses and methods to control body potential in memory operations
RU2015132550A (ru) 2013-01-23 2017-03-02 Ф. Хоффманн-Ля Рош Аг Противовирусные производные триазола
CN105452227B (zh) 2013-01-24 2018-05-29 菲布罗根有限公司 {[1-氰基-5-(4-氯苯氧基)-4-羟基-异喹啉-3-羰基]-氨基}-乙酸的晶形
US20140212491A1 (en) 2013-01-31 2014-07-31 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US20150065439A1 (en) 2013-02-28 2015-03-05 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
EP2964637B1 (en) 2013-03-05 2017-04-12 F. Hoffmann-La Roche AG Antiviral compounds
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
RU2534613C2 (ru) 2013-03-22 2014-11-27 Александр Васильевич Иващенко Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
US9249176B2 (en) 2013-05-16 2016-02-02 Riboscience Llc 4′-azido, 3′-deoxy-3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication
MA38675A1 (fr) 2013-05-16 2017-12-29 Riboscience Llc Dérivés de nucléosides 4'-fluoro-2'-méthyle substitués utiles pour inhiber la replication de l'hepatite c (hcv)
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
GB2518639B (en) 2013-09-26 2016-03-09 Dyson Technology Ltd A hand held appliance
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
MY196648A (en) 2016-02-05 2023-04-27 Denali Therapeutics Inc Inhibitors of Receptor-Interacting Protein Kinase 1
PT3552017T (pt) 2016-12-09 2022-05-04 Denali Therapeutics Inc Compostos úteis como inibidores de ripk1
GB201701087D0 (en) 2017-01-23 2017-03-08 Univ Leuven Kath Novel prodrugs of mizoribine
US10176880B1 (en) 2017-07-01 2019-01-08 Intel Corporation Selective body reset operation for three dimensional (3D) NAND memory
AR112702A1 (es) 2017-09-21 2019-11-27 Riboscience Llc Derivados de nucleósidos sustituidos con 4’-fluoro-2’-metilo como inhibidores de la replicación de hcv arn
AU2019351912B2 (en) * 2018-10-02 2025-07-31 Disc Medicine, Inc. Matriptase 2 inhibitors and uses thereof
JP7479486B2 (ja) * 2020-01-29 2024-05-08 フォグホーン セラピューティクス インコーポレイテッド 化合物およびその使用
KR102318294B1 (ko) * 2021-07-15 2021-10-26 이용화 친환경 교면방수제 조성물 및 이를 이용한 방수공법
AU2022380979A1 (en) 2021-11-02 2024-06-06 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof
TW202334164A (zh) 2022-01-12 2023-09-01 美商戴納立製藥公司 （Ｓ）－５－苄基－Ｎ－（５－甲基－４－側氧基－２，３，４，５－四氫吡啶並［３，２－ｂ］［１，４］氧氮呯－３－基）－４Ｈ－１，２，４－三唑－３－甲醯胺的晶型

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1094903A (en) 1964-03-26 1967-12-13 Smith Kline French Lab Improvements in or relating to nitrofuran derivatives
FR1604809A (en) 1965-11-26 1972-04-17 Thiazolyl benzimidazoles - animal feed additives
GB1186504A (en) 1966-10-15 1970-04-02 Fisons Pest Control Ltd Substituted Heterocyclic Compounds
NL6917115A (es) 1968-11-22 1970-05-26
US3565912A (en) 1969-01-27 1971-02-23 Upjohn Co 5-lower-alkanoyl-2,3-bis(p-methoxyphenyl)indoles
DE2346316C2 (de) 1973-09-14 1985-02-14 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von 2-Furylbenzimidazolen
GB1509527A (en) 1974-06-05 1978-05-04 Ici Ltd 1-(aryl-or heteroaryl)oxy-3-(substituted-amino)propan-2-ol derivatives processes for their manufacture and pharmaceutical compositions containing them
FR2291749A1 (fr) 1974-11-20 1976-06-18 Delalande Sa Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique
US4003908A (en) * 1976-03-11 1977-01-18 E. R. Squibb & Sons, Inc. Derivatives of imidazo(4,5-b)pyridines
CH632628B (de) * 1976-07-26 Ciba Geigy Ag Verfahren zur herstellung von benzofuranyl-benzimidazolen und deren verwendung als optische aufheller.
DE2641060A1 (de) 1976-09-11 1978-03-16 Hoechst Ag Beta-lactamverbindungen und verfahren zu ihrer herstellung
US4264325A (en) * 1977-02-22 1981-04-28 Ciba-Geigy Corporation Phenyl-benzimidazolyl-furanes for optical brightening of organic materials
DE2720111A1 (de) 1977-05-05 1978-11-16 Agfa Gevaert Ag Korrosionsschutzmittel fuer zweibad-stabilisatorbaeder
EP0010063B1 (de) 1978-10-04 1982-12-29 Ciba-Geigy Ag Verfahren zur Herstellung von Furanyl-benzazolen
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
DE2852531A1 (de) 1978-12-05 1980-06-19 Bayer Ag Benzofuranyl-benzimidazole
DE2853765A1 (de) 1978-12-13 1980-06-26 Bayer Ag Verfahren zur herstellung von benzimidazolylbenzofuranen
DE2904829A1 (de) 1979-02-08 1980-08-14 Bayer Ag Verfahren zur herstellung von benzimidazolylbenzofuran
EP0029003B1 (de) * 1979-11-01 1984-12-05 Ciba-Geigy Ag Salze kationischer Aufheller, deren Herstellung und deren Verwendung auf organischen Materialien sowie deren konzentrierte wässrige Lösungen
GR75101B (es) 1980-10-23 1984-07-13 Pfizer
GB8707798D0 (en) 1987-04-01 1987-05-07 Ici Plc Recovery of metals
ZA825413B (en) 1981-08-26 1983-06-29 Pfizer Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them
GB2118552A (en) 1982-04-15 1983-11-02 Pfizer Ltd Thromboxane synthetase inhibitors
JPS60149502A (ja) 1984-01-12 1985-08-07 Kuraray Co Ltd インド−ル系農園芸用殺菌剤
US4613990A (en) * 1984-06-25 1986-09-23 At&T Bell Laboratories Radiotelephone transmission power control
LU85544A1 (fr) * 1984-09-19 1986-04-03 Cird Derives heterocycliques aromatiques,leur procede de preparation et leur application dans les domaines therapeutique et cosmetique
DE3522230A1 (de) 1985-06-21 1987-01-02 Thomae Gmbh Dr K Neue 2-arylimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
GB8609175D0 (en) 1986-04-15 1986-05-21 Ici America Inc Heterocyclic carboxamides
US4859684A (en) * 1986-09-15 1989-08-22 Janssen Pharmaceutica N.V. (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and use thereof in treating androgen dependent disorders
CA1322005C (en) 1987-11-25 1993-09-07 Robert N. Young Benzoheterazoles
JP2700475B2 (ja) 1988-07-30 1998-01-21 コニカ株式会社 非線形光学材料および非線形光学素子
JPH03157646A (ja) 1989-11-15 1991-07-05 Konica Corp ハロゲン化銀写真感光材料
JPH03219232A (ja) 1990-01-24 1991-09-26 Konica Corp 分光増感されたハロゲン化銀写真感光材料
JPH05507469A (ja) 1990-04-13 1993-10-28 スミスクライン・ビーチャム・コーポレイション 置換ベンズイミダゾール
JP2909645B2 (ja) 1990-05-28 1999-06-23 コニカ株式会社 ハロゲン化銀カラー写真感光材料
DE10399008I1 (de) 1990-12-14 2006-06-08 Smithkline Beecham Corp Angiotensin-II-Rezeptor blockierende Zusammensetzungen
US5527819A (en) * 1991-09-06 1996-06-18 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9121463D0 (en) 1991-10-10 1991-11-27 Smithkline Beecham Corp Medicament
GB9122590D0 (en) 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
JPH05165163A (ja) 1991-12-11 1993-06-29 Konica Corp 色素画像形成方法
JP3013124B2 (ja) 1991-12-26 2000-02-28 コニカ株式会社 カラー画像形成方法
US5216003A (en) * 1992-01-02 1993-06-01 G. D. Searle & Co. Diacid-containing benzimidazole compounds for treatment of neurotoxic injury
GB9203798D0 (en) * 1992-02-21 1992-04-08 Fujisawa Pharmaceutical Co Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
US5314796A (en) 1992-04-02 1994-05-24 Konica Corporation Silver halide color photographic light sensitive material
US5387600A (en) 1992-07-30 1995-02-07 Fuji Photo Film Co., Ltd. Treating arteriosclerosis using benzimidazole compositions
DE4237557A1 (de) 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
DE4237617A1 (de) * 1992-11-06 1994-05-11 Bayer Ag Verwendung von substituierten Benzimidazolen
NZ257955A (en) 1992-12-02 1996-05-28 Pfizer Catechol diethers pharmaceutical compositions
JP3213426B2 (ja) * 1993-02-19 2001-10-02 エーザイ株式会社 ６，７−ジヒドロ−５Ｈ−シクロペンタ〔ｄ〕ピリミジン誘導体
DE69434016T2 (de) 1993-03-04 2005-02-10 Fuji Photo Film Co., Ltd., Minami-Ashigara Photographisches Silberhalogenidmaterial
DE4309969A1 (de) 1993-03-26 1994-09-29 Bayer Ag Substituierte heteroanellierte Imidazole
US6169107B1 (en) * 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives
JP3156444B2 (ja) 1993-06-02 2001-04-16 松下電器産業株式会社 短波長レーザ光源およびその製造方法
DE4330959A1 (de) 1993-09-09 1995-03-16 Schering Ag Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
EP0669323B2 (de) 1994-02-24 2004-04-07 Haarmann & Reimer Gmbh Kosmetische und dermatologische zubereitungen, enthaltend phenylen-1,4-bisbenzimidiazolesulfonsäuren
CA2124169A1 (en) 1994-05-24 1995-11-25 Richard Mcculloch Keenan Chemical compounds
EP0763026B1 (en) 1994-05-27 2003-03-26 James Black Foundation Limited Gastrin and cck antagonists
RO118426B1 (ro) 1994-11-29 2003-05-30 Dainippon Pharmaceutical Co Derivati de indol utilizati pentru tratarea diabetului zaharat si a obezitatii
EP0717143A1 (de) 1994-12-16 1996-06-19 Lignozym GmbH Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung
DE19507913C2 (de) 1995-03-07 1998-04-16 Agfa Gevaert Ag Farbfotografisches Silberhalogenidmaterial
CN1187812A (zh) * 1995-04-10 1998-07-15 藤泽药品工业株式会社 作为环状乌苷3',5'－一磷酸盐磷酸二酯酶抑制剂的吲哚衍生物
KR100430059B1 (ko) 1995-04-10 2004-09-24 후지사와 야꾸힝 고교 가부시키가이샤 cGMP-PDE억제제로서의인돌유도체
US6444694B1 (en) 1995-06-06 2002-09-03 Wyeth Styryl benzimidazole derivatives
JP3544245B2 (ja) 1995-06-09 2004-07-21 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料の処理方法
US5866594A (en) * 1995-08-04 1999-02-02 Otsuka Kagaku Kabushiki Kaisha Indole-2-carboxylate derivatives and fungicidal compositions for agricultural or horticultural use containing the derivatives as active component
US5950124A (en) * 1995-09-06 1999-09-07 Telxon Corporation Cellular communication system with dynamically modified data transmission parameters
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
NZ318874A (en) * 1995-10-05 1999-09-29 Kyoto Pharma Ind Indoline and quinoline derivatives, preparation and pharmaceutical compositions thereof
JPH09124632A (ja) 1995-10-31 1997-05-13 Sankyo Co Ltd ベンゾヘテロ環誘導体
CA2241186C (en) 1995-12-28 2006-02-14 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
US5850592A (en) * 1996-01-11 1998-12-15 Gte Internetworking Incorporated Method for self-organizing mobile wireless station network
JP2803626B2 (ja) * 1996-04-05 1998-09-24 日本電気株式会社 移動無線端末の送信電力制御方式
GB9610811D0 (en) 1996-05-23 1996-07-31 Pharmacia Spa Combinatorial solid phase synthesis of a library of indole derivatives
CA2258728C (en) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
GB9614347D0 (en) 1996-07-09 1996-09-04 Smithkline Beecham Spa Novel compounds
AUPO118896A0 (en) 1996-07-23 1996-08-15 Fujisawa Pharmaceutical Co., Ltd. New use
EP0923582B1 (en) 1996-08-28 2006-09-20 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
JPH10114654A (ja) 1996-10-09 1998-05-06 Fujisawa Pharmaceut Co Ltd 新規用途
EP0949259B1 (en) 1996-12-26 2001-06-20 Nikken Chemicals Company, Limited N-hydroxyurea derivatives and medicinal compositions containing the same
JPH10204059A (ja) 1997-01-22 1998-08-04 Ono Pharmaceut Co Ltd フェニルスルホンアミド誘導体
DE69836422T2 (de) 1997-02-19 2007-06-14 Berlex, Inc., Richmond N-heterocyclische derivate als nos inhibitoren
CA2279211A1 (en) 1997-02-20 1998-08-27 Shionogi & Co., Ltd. Indole dicarboxylic acid derivatives
US6089156A (en) * 1997-03-21 2000-07-18 Heidelberger Druckmaschinen Aktiengesellschaft Turning device for a printing press
US5932743A (en) * 1997-08-21 1999-08-03 American Home Products Corporation Methods for the solid phase synthesis of substituted indole compounds
DE19753522A1 (de) 1997-12-03 1999-06-10 Boehringer Ingelheim Pharma Substituierte Indole, ihre Herstellung und ihre Verwendung als Arzneimittel
SE9704544D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
EP1037974B1 (en) 1997-12-11 2007-10-03 SmithKline Beecham Corporation Hepatitis c virus ns5b truncated protein and methods thereof to identify antiviral compounds
JPH11177218A (ja) 1997-12-12 1999-07-02 Tamura Kaken Co Ltd 電子回路用金属面具備部品及びその表面保護剤
US6104512A (en) * 1998-01-23 2000-08-15 Motorola, Inc. Method for adjusting the power level of an infrared signal
KR100291413B1 (ko) * 1998-03-02 2001-07-12 김영환 이동통신단말기의송신전력제어장치
CA2332999A1 (en) 1998-05-22 1999-12-02 Avanir Pharmaceuticals Compounds having ige affecting properties
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
JP2002518381A (ja) 1998-06-18 2002-06-25 ノバルテイス・アクチエンゲゼルシヤフト ベンザゾール化合物およびその使用
US7223879B2 (en) * 1998-07-10 2007-05-29 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
AU5227999A (en) 1998-07-27 2000-02-21 Abbott Laboratories Substituted oxazolines as antiproliferative agents
US6492423B1 (en) 1998-07-27 2002-12-10 Istituto Di Ricerche Di Biologia Molecolare Pangeletti Spa Diketoacid-derivatives as inhibitors of polymerases
US6228868B1 (en) * 1998-07-27 2001-05-08 Abbott Laboratories Oxazoline antiproliferative agents
CA2341970A1 (en) 1998-08-21 2000-03-02 Viropharma Incorporated Compounds, compositions and methods for treating or preventing viral infections and associated diseases
WO2000013708A1 (en) 1998-09-04 2000-03-16 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
JP2002525295A (ja) 1998-09-25 2002-08-13 バイロファーマ・インコーポレイテッド ウイルス感染および関連疾患の治療または予防法
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
AU755552B2 (en) 1998-11-12 2002-12-12 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
US6358992B1 (en) 1998-11-25 2002-03-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with indole derivatives
WO2000039099A1 (en) 1998-12-24 2000-07-06 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
ATE241621T1 (de) 1999-04-02 2003-06-15 Bristol Myers Squibb Pharma Co Arylsulfonyle als faktor xa inhibitoren
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
US6346493B1 (en) * 1999-10-27 2002-02-12 Ferro Corporation Decorative glass enamels
JP2001122855A (ja) 1999-10-27 2001-05-08 Japan Tobacco Inc インドール化合物及びその医薬用途
NL1013456C2 (nl) * 1999-11-02 2001-05-03 Dsm Nv Kristallijn melamine en de toepassing in aminoformaldehydeharsen.
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
CA2395593C (en) 1999-12-24 2011-08-02 Aventis Pharma Limited Azaindoles
US6770666B2 (en) * 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
NZ514403A (en) 1999-12-27 2002-10-25 Japan Tobacco Inc Fused-ring compounds and use thereof as drugs
JP2003519697A (ja) 1999-12-28 2003-06-24 ファイザー・プロダクツ・インク 炎症性疾患、自己免疫疾患および呼吸器疾患の処置に有用な非ペプチド系のｖｌａ−４依存性細胞結合阻害薬
GB0003397D0 (en) * 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
EP1292310A1 (en) 2000-05-10 2003-03-19 SmithKline Beecham Corporation Novel anti-infectives
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
US6765484B2 (en) * 2000-09-07 2004-07-20 Savi Technology, Inc. Method and apparatus for supplying commands to a tag
US6940392B2 (en) * 2001-04-24 2005-09-06 Savi Technology, Inc. Method and apparatus for varying signals transmitted by a tag
KR100828453B1 (ko) 2001-01-22 2008-05-13 머크 앤드 캄파니 인코포레이티드 Ｒｎａ 의존성 ｒｎａ 바이러스 폴리머라제의억제제로서의 뉴클레오시드 유도체
GB0102109D0 (en) 2001-01-26 2001-03-14 Syngenta Ltd Chemical process
WO2002069903A2 (en) 2001-03-06 2002-09-12 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
IL157280A0 (en) * 2001-03-08 2004-02-19 Boehringer Ingelheim Ca Ltd Assay for identifying inhibitors of the rna dependent rna polymerase (ns5b) of hcv
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
US6887877B2 (en) 2001-06-11 2005-05-03 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
ATE438637T1 (de) 2001-06-11 2009-08-15 Virochem Pharma Inc Thiophenderivate als antivirale mittel gegen flavivirus-infektion
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
JP2003212846A (ja) * 2001-06-26 2003-07-30 Japan Tobacco Inc 縮合環化合物及びｃ型肝炎治療剤
EP1411928A1 (en) * 2001-07-20 2004-04-28 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US7294457B2 (en) 2001-08-07 2007-11-13 Boehringer Ingelheim (Canada) Ltd. Direct binding assay for identifying inhibitors of HCV polymerase
JP2005503393A (ja) 2001-08-22 2005-02-03 チバ　スペシャルティ　ケミカルズ　ホールディング　インコーポレーテッド インドール誘導体の製造方法
US20030134853A1 (en) * 2001-09-26 2003-07-17 Priestley Eldon Scott Compounds useful for treating hepatitis C virus
UA79248C2 (en) 2001-11-09 2007-06-11 Janssen Pharmaceutica Nv Mandelate salts of substituted tetracyclic tetrahydrofuran derivatives
CA2487211C (en) 2002-06-04 2010-09-14 Neogenesis Pharmaceuticals, Inc. Pyrazolo(1,5a) pyrimidine compounds as antiviral agents
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
US7098231B2 (en) * 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) * 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7286844B1 (en) * 2003-01-31 2007-10-23 Bbn Technologies Corp. Systems and methods for three dimensional antenna selection and power control in an Ad-Hoc wireless network
GB0307891D0 (en) 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
JP2007501189A (ja) 2003-08-01 2007-01-25 ジェネラブス テクノロジーズ，インコーポレイテッド フラビウイルス科に対する二環式イミダゾール誘導体
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
US7136667B2 (en) * 2003-10-28 2006-11-14 Nokia Corporation Method and radio terminal equipment arrangement for power control, radio terminal equipment and secondary terminal unit
US7212122B2 (en) * 2003-12-30 2007-05-01 G2 Microsystems Pty. Ltd. Methods and apparatus of meshing and hierarchy establishment for tracking devices
CN102911161A (zh) * 2004-02-20 2013-02-06 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
CN1930124A (zh) * 2004-03-08 2007-03-14 贝林格尔·英格海姆药物公司 制备交叉偶联吲哚的方法
CA2558051C (en) * 2004-03-16 2013-03-12 Boehringer Ingelheim International Gmbh Palladium catalyzed indolization of 2-bromo or chloroanilines
US7348875B2 (en) * 2004-05-04 2008-03-25 Battelle Memorial Institute Semi-passive radio frequency identification (RFID) tag with active beacon
PE20060569A1 (es) * 2004-07-16 2006-06-22 Boehringer Ingelheim Int Compuestos de indol carbonilamino como inhibidores de la polimerasa ne5b del vhc
US7342497B2 (en) * 2004-08-26 2008-03-11 Avante International Technology, Inc Object monitoring, locating, and tracking system employing RFID devices
US7319397B2 (en) * 2004-08-26 2008-01-15 Avante International Technology, Inc. RFID device for object monitoring, locating, and tracking
EP1853589A1 (en) * 2005-02-11 2007-11-14 Boehringer Ingelheim International Gmbh Process for preparing 2,3-disubstituted indoles

Also Published As

Publication number Publication date
SI1414441T1 (sl) 2008-06-30
DE60224401T2 (de) 2009-01-02
JP2009120616A (ja) 2009-06-04
ES2299591T3 (es) 2008-06-01
IL222761A0 (en) 2012-12-31
PT1414441E (pt) 2008-03-07
CA2449180C (en) 2010-04-27
KR20040023674A (ko) 2004-03-18
MY151080A (en) 2014-04-15
US20060293306A1 (en) 2006-12-28
US20090087409A1 (en) 2009-04-02
PT1414797E (pt) 2008-02-14
HUP0401784A3 (en) 2011-03-28
UA84256C2 (en) 2008-10-10
CY1107355T1 (el) 2012-12-19
MEP62108A (en) 2011-05-10
EA007722B1 (ru) 2006-12-29
KR20100002296A (ko) 2010-01-06
PL372125A1 (en) 2005-07-11
US7803944B2 (en) 2010-09-28
DK1414441T3 (da) 2008-05-13
NZ531229A (en) 2006-03-31
EP1414797B1 (en) 2008-01-02
DK1414797T3 (da) 2008-05-13
JP2005504030A (ja) 2005-02-10
US20030176433A1 (en) 2003-09-18
RS20090517A (sr) 2010-05-07
HRP20040072A2 (en) 2004-06-30
EP1414797A2 (en) 2004-05-06
BR0211360A (pt) 2004-07-13
IL159649A0 (en) 2004-06-01
CO5650161A2 (es) 2006-06-30
CN1558759B (zh) 2012-01-25
US7576079B2 (en) 2009-08-18
BR0211477A (pt) 2004-08-17
WO2003010141A3 (en) 2003-05-30
HUP0402065A2 (hu) 2005-02-28
NO333121B1 (no) 2013-03-04
HRP20040073A2 (en) 2004-06-30
CN1610546A (zh) 2005-04-27
DE60224400D1 (de) 2008-02-14
AR037495A1 (es) 2004-11-17
HK1069991A1 (en) 2005-06-10
HUP0402065A3 (en) 2013-06-28
US20060160798A1 (en) 2006-07-20
NO327055B1 (no) 2009-04-14
EA200400114A1 (ru) 2004-08-26
NZ531267A (en) 2006-02-24
RS7004A (sr) 2006-12-15
HRP20040073B1 (en) 2012-02-29
JP2004537564A (ja) 2004-12-16
EA007715B1 (ru) 2006-12-29
JP4398725B2 (ja) 2010-01-13
YU6904A (sh) 2006-08-17
EA200400113A1 (ru) 2004-08-26
US7141574B2 (en) 2006-11-28
AU2002355150B2 (en) 2008-08-07
AU2002313410B2 (en) 2008-09-11
NO20040282L (no) 2004-01-21
PL368357A1 (en) 2005-03-21
JP4398241B2 (ja) 2010-01-13
EP2335700A1 (en) 2011-06-22
SI1414797T1 (sl) 2008-06-30
KR20040023675A (ko) 2004-03-18
MEP59608A (en) 2011-05-10
DE60224401D1 (de) 2008-02-14
DE60224400T2 (de) 2008-12-18
HRP20090668A2 (hr) 2010-07-31
EP1414441B1 (en) 2008-01-02
US20040024190A1 (en) 2004-02-05
AR073106A2 (es) 2010-10-13
CA2450033A1 (en) 2003-02-06
UY27397A1 (es) 2003-02-28
WO2003010141A2 (en) 2003-02-06
KR100950868B1 (ko) 2010-04-06
ES2299588T3 (es) 2008-06-01
EP1414797B9 (en) 2009-04-15
EP1891951A1 (en) 2008-02-27
HRP20040072B1 (en) 2012-01-31
ATE382348T1 (de) 2008-01-15
HK1073786A1 (zh) 2005-10-21
RS51083B (sr) 2010-10-31
KR100949446B1 (ko) 2010-03-29
MXPA04000729A (es) 2004-06-25
WO2003010140A2 (en) 2003-02-06
CN100443469C (zh) 2008-12-17
CA2449180A1 (en) 2003-02-06
EP1414441A2 (en) 2004-05-06
IL159545A (en) 2013-11-28
SG176999A1 (en) 2012-01-30
CY1107354T1 (el) 2012-12-19
HUP0401784A2 (hu) 2004-12-28
RS50843B (sr) 2010-08-31
EP1891950A1 (en) 2008-02-27
CN1558759A (zh) 2004-12-29
US7893084B2 (en) 2011-02-22
CO5650162A2 (es) 2006-06-30
CN102424680A (zh) 2012-04-25
JP2009275037A (ja) 2009-11-26
MXPA04000731A (es) 2004-06-25
KR101031183B1 (ko) 2011-04-26
ATE382605T1 (de) 2008-01-15
WO2003010140A3 (en) 2003-07-10
IL159545A0 (en) 2004-06-01
US7157486B2 (en) 2007-01-02
NO20040322L (no) 2004-02-26
CA2450033C (en) 2009-07-07

Similar Documents

Publication Publication Date Title
PE20030305A1 (es) Inhibidores de polimerasas viricas
DE60140127D1 (en) Dihydroxypyrimidin-carbonsäuren als virale polymerase inhibitoren
NO20064004L (no) Virale polymeraseinhibitorer
CO5550398A2 (es) 7-aminotriazolpirimidinas, proceso e intermedios para su preparacion, composiciones que las comprenden y su uso para controlar hongos dañinos
WO2003014377A3 (en) Competitive binding assay for identifying inhibitors of hcv polymerase
NO20071274L (no) Inhibitorer av hepatitt C virus RNA-avhengig RNA polymerase, og sammensetninger og behandlinger ved anvendelse av samme.
MX2007000007A (es) Inhibidores de polimerasa viral.
YU34796A (sh) Supstituisani n(indol-2-karbonil) гћві -alaninamid, njihovi derivati i farmaceutske smeše koje ih sadrže
NI201000130A (es) Derivados de urea de tetrahidroquinoxalina, su preparación y su aplicación en terapéutica.
NO20082934L (no) Antivirale nukleotider
HK1054547A1 (zh) 取代的脲神经肽yy5受体拮抗剂
NZ526703A (en) Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
AR061581A1 (es) Compuestos de pirro[1,2-b]piridazinona,composiciones farmaceuticas que los contienen y usos para tratar hepatitis c.
ES2192520T3 (es) Composicion farmaceutica.
CO5700820A2 (es) Derivados de dioxan-2-alquilcarbamatos, su preparacion y su aplicacion en terapeutica
PE20021074A1 (es) Derivados de n-oxiantranilamida y los medicamentos que los contienen
AR038404A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4, procedimiento para la preparacion del compuesto y composicion farmaceutica que lo incluye
CO6251235A2 (es) Compuestos derivados de azetidinas su preparacion y su aplicacion en terapeutica
DE602005014804D1 (de) Substituierte 5-carboxyamidpyrazoles und ä1,2,4ütriazole als viruzide
CO5550437A2 (es) Compuestos quimicos
AR057980A1 (es) Derivados de la 1- amino-ftalazina sustituida, su preparacion y composicion farmaceutica
AR027335A1 (es) Compuestos de piperidina-4-sulfonamida, proceso de preparacion de los mismos, y composiciones farmaceuticas que los contienen
AR006747A1 (es) Compuestos herbicidas de pirazol sustituidos, composicion herbicida que los comprende y metodo de aplicacion de los mismos.
DE60201089D1 (de) 6-(2-chlor-6-fluor-phenyl)-triazolpyrimidine
AR066743A1 (es) Inhibidores no nucleosidos de la transcriptasa inversa

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed